Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Affiliations Topics Sessions Videos Audios Previous meetings

Topics

Select Topic

Showing 1,267 results.

$Thumbnail for CD20ΧCD3 Bispecific Antibodies in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Systematic Review$

ABCL - 324

CD20ΧCD3 Bispecific Antibodies in Relapsed or Refractory Primary Central Nervous System Lymphoma: A Systematic Review

Anamika Adib

Poster Presenter: Anamika Adib

Thumbnail for BTK Inhibitors Combined With High-Dose Methotrexate-Based Induction in Newly Diagnosed Primary CNS Lymphoma: A Systematic Review and Meta-Analysis

ABCL - 325

BTK Inhibitors Combined With High-Dose Methotrexate-Based Induction in Newly Diagnosed Primary CNS Lymphoma: A Systematic Review and Meta-Analysis

Anamika Adib

Poster Presenter: Anamika Adib

Previous 1...6 7 8 9 10 11 12...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

Thumbnail for Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-Cel) and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma

ABCL - 346

Real-World Comparative Study of the Effectiveness, Safety, and Health Care Resource Utilization of Lisocabtagene Maraleucel (Liso-Cel) and Bispecific Antibodies in Third-Line or Later Large B-Cell Lymphoma

Sagar Patel

Poster Presenter: Sagar Patel

Thumbnail for Therapeutic Architecture Rather Than Population Differences Drives Frontline Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts

ABCL - 397

Therapeutic Architecture Rather Than Population Differences Drives Frontline Outcomes in T-Cell/Histiocyte-Rich Large B-Cell Lymphoma: A Comparison-Specific Pooled Analysis of Rituximab-Era Cohorts

Adarsh Vardhan Tangella

Poster Presenter: Adarsh Vardhan Tangella

Thumbnail for Impact of COVID-19 on Hematologic Malignancy Mortality: A Comparative Analysis of Pre-COVID (2015-2019) and COVID-Era (2020-2023) US Death Rates

ABCL - 399

Impact of COVID-19 on Hematologic Malignancy Mortality: A Comparative Analysis of Pre-COVID (2015-2019) and COVID-Era (2020-2023) US Death Rates

Madho Mal

Poster Presenter: Madho Mal

Thumbnail for Obesity and Outcomes After Bone Marrow Transplant in Patients With Lymphoma: A Real-World TriNetX Study

ABCL - 408

Obesity and Outcomes After Bone Marrow Transplant in Patients With Lymphoma: A Real-World TriNetX Study

Nayanika Tummala

Poster Presenter: Nayanika Tummala

$Thumbnail for Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups$

ABCL - 438

Mosunetuzumab Plus Polatuzumab Vedotin (Mosun-Pola) vs Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) in Patients With Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line (2L) vs Third-Line Plus (3L+) Patient Subgroups

Jason Westin

Poster Presenter: Jason Westin

Thumbnail for Cross-disease stratification by genetic classifier Lymphly reveals shared molecular programs across B-cell malignancies

ABCL - 443

Cross-disease stratification by genetic classifier Lymphly reveals shared molecular programs across B-cell malignancies

Mark Meerson

Poster Presenter: Mark Meerson

$Thumbnail for Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO$

ABCL - 483

Glofitamab Plus Gemcitabine and Oxaliplatin (GemOx) Versus Rituximab Plus GemOx (R-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the 3-Year Follow-Up of STARGLO

Haifaa Abdulhaq

Poster Presenter: Haifaa Abdulhaq

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors